Highlights of weekly biotech stock moves

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.60 to $24.21 last week after completing submission of a rolling NDA to FDA seeking accelerated approval of ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ariad, which requested Priority Review, began the submission in late July, and hopes to launch the product in the U.S. in 1Q13.

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) lost $0.02 to $3.08 on Friday after the European Commission approved an MAA from Johnson & Johnson (NYSE:JNJ) for Dacogen decitabine to treat newly diagnosed de novoor secondary acute myelogenous leukemia (AML) in patients 65 years and older...